brf2-knocked-down zebrafish. A Touch-response test showing the percentage of the classified swimming movements upon a tactile stimulus on the tail for uninjected (Un), mock-injected (Mock), brf2-knocked down (brf2-KD) zebrafish larvae at 3 dpf. The number of tested larvae is indicated in parenthesis. B Head width (indicated by white arrows in the left panel) measurements Un-, Mock, brf2brf2-KD, and brf2-KD co-injected with human mRNA BRF2 wild-type (hBRF2-WT), Gly11Ser (hBRF2-G11S), Pro261Leu (hBRF2-P261L), Gly161* (hBRF2-G161*), Met135Asnfs*15 (hBRF2-M135Nfs*). The number of tested larvae is indicated in parenthesis. C Swimming fast velocity in the dark of Un, Mock, brf2-KD, and brf2-KD co-injected with human mRNA BRF2 wild-type (hBRF2-WT), Gly11Ser (hBRF2-G11S), Pro261Leu (hBRF2-P261L), Gly161* (hBRF2-G161*), Met135Asnfs*15 (hBRF2-M135Nfs*). D Alcian blue staining in zebrafish larvae at 5 dpf. On the left, representative ventral pictures of the Alcian blue staining showing jaw malformations of brf2-KD co-injected with human RNA BRF2 Pro261Leu (hBRF2-P261L 200 pg), Gly161* (hBRF2-G161* 200 pg), Met135Asnfs*15 (hBRF2-M135Nfs* 200 pg), and half dose of BRF2 Gly11Ser RNA (hBRF2-G11S 100 pg) compared with illustrative pictures of the normal jaw structure observed in Un, Mock, and brf2-KD co-injected with human BRF2 wildtype at normal (hBRF2-WT 200 pg) and half dosage (hBRF2-WT 100 pg) and Gly11Ser (hBRF2-G11S 200 pg). The fraction of the observed deformed jaw structure is presented in the right panel as a percentage. *** P < 0.001; ** P < 0.005; ns = not significant; § significant vs brf2- KD (P < 0.05); ¤ significant vs Mock (P < 0.05); † significant vs h BRF2 -WT (P < 0.05); α significant vs Un (P < 0.05)
|